Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sano Habitrol generic transdermal patch could be marketed by Par Pharmaceuticals.

This article was originally published in The Tan Sheet

Executive Summary

SANO HABITROL GENERIC PATCH COULD BE MARKETED BY PAR if FDA approves the company's ANDA for a version of Ciba's nicotine transdermal patch for smoking cessation, according to a recent prospectus for a proposed public offering. Sano filed its ANDA in January 1995, has "received comments from the FDA...and has responded to those comments," the prospectus states. Miramar, Fla.-based Sano's manufacturing facilities passed an FDA preapproval inspection in July 1996. Ciba's Habitrol patents expire in 2003 and 2006.
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS086440

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel